Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ILU.DE
Strong BuyIllumina, Inc. · Healthcare · United States · $33.3B · Avg Vol: $20K/d
88
StockRankGet insider-trade alerts
Q
78
V
25
M
84
P/E (TTM)
40.2x
ROE
32.3%
D/E
0.9x
Dividend %
—
COMPANY DESCRIPTION
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.0B | 3.9B | 3.8B | 3.7B | -1.8% | 3.9B | 4.0B | 4.2B | 6.3% |
| EPS (EUR) | -24.03 | -6.29 | -6.63 | 4.79 | — | 4.73 | — | — | — |
| Shares | 158.0M | 159.0M | 159.0M | 153.0M | -3.2% | 151.0M | — | — | — |
| Debt | 3.1B | 1.9B | 2.3B | 2.2B | -10.4% | 2.2B | — | — | — |
| Equity | 5.7B | 5.0B | 2.0B | 2.3B | -25.6% | — | — | — | — |
| Op CF | 337.9M | 412.0M | 721.5M | 930.1M | 40.1% | 943.9M | — | — | — |
| Inv CF | -509.4M | -199.1M | -153.4M | -47.4M | — | — | — | — | — |
| Fin CF | 862.0M | -1.0B | -491.3M | -641.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+21.7%
SMA 50SMA 200
Close
$228.05
RSI (14)
75.4
52W High
$228.19
From 52W High
1.0%
SCORE BREAKDOWN
Quality
78
ROIC
23.5%93.7
ROE
32.3%94.9
GP/Assets
46.0%84.1
Op. Margin
21.1%83.3
FCF/Assets
14.6%92.3
Piotroski
894.4
Int. Cover
11.8x64.7
D/E Ratio
0.89x17.2
Current Ratio
1.80x34.8
Value
25
P/E (TTM)
40.2x25.7
EV/EBITDA
30.2x19.2
P/FCF
34.5x38.5
P/B
13.7x8.6
P/S
7.4x32.4
Div Yield
—N/A
Momentum
84
52W High %
100%99.6
RS 6M
61%92.5
SMA 50/200
1.33x95.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-12%29.0
FUNDAMENTALS
Market Cap
$33.3B
P/E (Forward)
—
Gross Margin
67.9%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ILU.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ILU.DE | Illumina, Inc.(you) | $33.3B | 88 | Strong Buy |
| A1GI34.SA | Agilent Technologies, Inc. | $39.1B | 87 | Strong Buy |
| LH | Labcorp Holdings Inc. | $27.2B | 86 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $26.8B | 85 | Strong Buy |
| IQV | IQVIA Holdings Inc. | $43.1B | 78 | Buy |
| MEDP | Medpace Holdings, Inc. | $16.8B | 84 | Strong Buy |
| IDXX.MX | IDEXX Laboratories, Inc. | $43.9B | 73 | Buy |
| WAT | Waters Corporation | $40.7B | 63 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 67 | Buy |
| NTRA | Natera, Inc. | $47.0B | 56 | Hold |
Peer medians: ROE -25.0% · P/E 29.6x · Gross margin 58.8%